Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Fistulizing, Perianal Crohn's Disease
NCT05347095Phase 3Active, not recruiting
- Sponsor
- Janssen-Cilag
- Start
- Sep 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen-Cilag. Started Sep 2022; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05347095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347095.